This is goofy, though. If it's the same product, there's a real reason it's more expensive here. It could be anything from excessive regulatory hurdles to a cash grab, but there's something wrong. Address the underlying issue.
This is goofy, though. If it's the same product, there's a real reason it's more expensive here. It could be anything from excessive regulatory hurdles to a cash grab, but there's something wrong. Address the underlying issue.
If the cost/benefit ratio is sufficient, a recommendation is made to the government, which then decides whether it will subsidize the drug. If it does, then the drug is provided to patients at a capped price (currently ~AUD40 for non-welfare recipients, ~AUD7 for welfare recipients), with the remainder of the cost paid by the government.
This provides a direct incentive to the pharma company to get their drug listed under the PBS, because it ensures that they have a large market available.
Drugs that are not available under the PBS are still available, but at full price to the patient. However, because of the expectations of pricing in our market, the pharma companies have to keep their prices lower overall.
It's not a new concept and it works with almost all commodities. If you need to buy iphones, you are likely to get a better price for them if you call Apple directly and ask to buy a batch of 10M than if you show up to an apple store to get 5 units.
India does that a lot, and supplies the entire developing world with medicines.
Canada doesn’t have that much leverage. It often receives brand medications much later, and some cases medications aren’t marketed in Canada.
Try to buy Nuvigil in Canada, let us know how that leverage worked out for this drug.